Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 938 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Respiratory Disease Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa

NCT02615119
View directory record Official record
Conditions
Anorexia Nervosa, Major Depressive Disorder, Generalized Anxiety Disorder, Panic Disorder, Brain Injury
Interventions
Isoproterenol, Normal saline
Drug
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 3 Interventional

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

NCT04701983
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab SAR440340, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
86
States / cities
Birmingham, Alabama • Jasper, Alabama • Chandler, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

NCT06785454
View directory record Official record
Conditions
Obstructive Sleep Apnea, Hypertension
Interventions
Lorundrostat, Placebo
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
27
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

NCT02796651
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease - COPD
Interventions
Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Placebo for formoterol fumarate, Formoterol fumarate (12 μg), Formoterol fumarate (40 μg)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01276639
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Birmingham, Alabama • Irvine, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 10, 2026, 5:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Severe Asthma Research Program III-Boston Clinical Site

NCT01761630
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Elliot Israel, MD
Other
Eligibility
6 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 10, 2026, 5:05 PM EDT
Completed No phase listed Observational

ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19

NCT04367740
View directory record Official record
Conditions
Asymptomatic Condition, Infection Viral, Coronavirus Infections, Severe Acute Respiratory Syndrome Coronavirus 2, Coronaviridae Infections, RNA Virus Infections, Virus Diseases, Communicable Disease
Interventions
To assess for development of IgG antibodies against SARS-CoV2
Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
6,313 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 10, 2026, 5:05 PM EDT
Completed No phase listed Observational Results available

Evaluation of Moderate to Severe Influenza Outcomes in Children

NCT02979626
View directory record Official record
Conditions
Influenza, Otitis Media, Lower Resp Tract Infection, Encephalitic Infection, Myositis Viral, Fever
Interventions
Respiratory nasal swab
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 8 Years
Enrollment
1,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Aurora, Colorado • Broomfield, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

NCT04470544
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome
Interventions
Camostat Mesilate, Standard of Care
Drug · Other
Lead sponsor
Alan Bryce
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Scottsdale, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

NCT07069309
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
12 Years and older
Enrollment
774 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
19
States / cities
Walnut Creek, California • Milford, Connecticut • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

NCT01709214
View directory record Official record
Conditions
Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions
Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
83
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cyclosporine For The Treatment Of COVID-19(+)

NCT04492891
View directory record Official record
Conditions
SARS (Disease)
Interventions
Cyclosporine, Standard of Care Treatment
Drug · Other
Lead sponsor
Bryan Burt, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

SPI-1005 Treatment in Severe COVID-19 Patients

NCT04483973
View directory record Official record
Conditions
Covid19, Coronavirus, Coronavirus Infection, Corona Virus Infection
Interventions
Ebselen, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
New Haven, Connecticut • Boise, Idaho • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

NCT05329194
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Mobile, Alabama • Gilbert, Arizona • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01013142
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
MN-221 (Dose Group 1), MN-221 (Dose Group 2), MN-221 (Dose Group 3)
Drug
Lead sponsor
MediciNova
Industry
Eligibility
40 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Fullerton, California • Tamarac, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 10, 2026, 5:05 PM EDT
No Longer Available No phase listed Expanded access

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

NCT04355494
View directory record Official record
Conditions
COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Newton, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 10, 2026, 5:05 PM EDT
Completed No phase listed Observational

Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT00281242
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions
blood draw
Other
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 10, 2026, 5:05 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Airway Redox and Gender Determinants in Severe Asthma

NCT01759186
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
6 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
4
States / cities
Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Washington University Severe Asthma Research Program III

NCT01716494
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.

NCT03170271
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab (Medi-563), Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
100
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 10, 2026, 5:05 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age

NCT07805707
View directory record Official record
Conditions
Influenza, Human
Interventions
mRNA Seasonal Flu vaccine, Licensed Influenza Vaccine
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
54,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
161
States / cities
Anniston, Alabama • Guntersville, Alabama • Glendale, Arizona + 128 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 10, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

NCT00019019
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, paclitaxel
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 10, 2026, 5:05 PM EDT
Completed No phase listed Observational

Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children

NCT04838834
View directory record Official record
Conditions
COVID-19, SARS-CoV-2, Inflammatory Bowel Diseases
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
2 Years to 27 Years
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 10, 2026, 5:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Genetics of Severe Asthma in Children

NCT01238432
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
4 Years to 18 Years
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 10, 2026, 5:05 PM EDT